January 14, 2021 -- Fujifilm Diosynth Biotechnologies has announced $76 million in financing for the Center for Advanced Biological Innovation and Manufacturing (CABIM) and that a lease for a site in the Boston area has been signed.
CABIM is an industry-academia research and development consortium aimed at accelerating development and commercialization of cell and gene therapy, gene editing, and immunotherapy. In addition to Fujifilm, it is backed by the following:
- Harvard University
- Massachusetts Institute of Technology
- Cytiva
- Alexandria Real Estate Equities
The lease covers a 40,000-sq-ft site at the Arsenal on the Charles business park in Watertown MA, which is owned and operated by Alexandria Real Estate. The $76 million in fundraising will be used to help build the site, support 40 full-time employees, and maintain daily operations. The new center is set to open early next year
Fujifilm Diosynth Biotechnologies, a contract development and management organization subsidiary of Fujifilm, is set to provide contract development and manufacturing services.
Copyright © 2021 scienceboard.net